8-K: IN8bio Reports Q3 2025 Results, Advances Gamma-Delta T Cell Programs

IN8bio, a clinical-stage biopharmaceutical company, announced its third quarter 2025 financial results and provided updates on its gamma-delta T cell therapy pipeline, including new preclinical data for INB-619 and expansion of the INB-100 trial.

Summary

• Reported third quarter 2025 financial results, including a net loss of $3.9 million, or $0.85 per basic and diluted common share, compared to a net loss of $7.1 million, or $4.49 per share, for the comparable prior year period.
• Cash position as of September 30, 2025, was $10.7 million, an increase from $4.0 million as of September 30, 2024.
• Research and Development (R&D) expenses decreased to $2.1 million for Q3 2025 from $3.3 million for Q3 2024, primarily due to a strategic pause on INB-400 clinical trial activities and personnel-related costs.
• General and Administrative (G&A) expenses decreased to $1.9 million for Q3 2025 from $2.7 million for Q3 2024, mainly due to cost savings in personnel, director and officer insurance premiums, and professional services.
• Presented new preclinical data on INB-619, a novel CD19 targeting gamma-delta T cell engager (TCE), demonstrating equivalent potency to FDA-approved commercial CD19 and CD20 engagers with minimal adverse cytokine release.
• Expanded the Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University to accelerate patient enrollment.
• Anticipates presenting updated Phase 1 and 2 data from the INB-200/400 program in newly diagnosed glioblastoma (GBM) at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting (November 19-23, 2025).
• Anticipates presenting additional preclinical data from the INB-619 gamma-delta T cell engager program in oncology at the American Society of Hematology (ASH) Annual Meeting (December 6-9, 2025).

Sentiment

Score: 7

Explanation: The company reported improved financial metrics with a reduced net loss and increased cash, alongside positive preclinical data and clinical trial expansion. However, it remains a clinical-stage company with ongoing losses and explicit risks related to future capital needs and trial outcomes.

Positives

• Net loss significantly decreased to $3.9 million in Q3 2025 from $7.1 million in Q3 2024, representing a substantial improvement in financial performance.
• Cash position increased to $10.7 million as of September 30, 2025, from $4.0 million as of September 30, 2024, indicating improved liquidity.
• R&D and G&A expenses decreased due to strategic cost savings and pipeline prioritization, demonstrating effective financial management.
• New preclinical data for INB-619 showed equivalent efficacy to FDA-approved CD19 and CD20 engagers (blinatumomab, mosunetuzumab) in eliminating B cells in systemic lupus erythematosus (SLE) donor models.
• INB-619 demonstrated minimal cytokine release, suggesting a potentially improved safety profile over conventional CD3-directed engagers and allowing for higher doses and deeper B cell depletion.
• Expansion of the Phase 1 INB-100 trial to The Ohio State University is expected to accelerate patient enrollment, advancing clinical development.

Negatives

• The company continues to report a net loss of $3.9 million for the quarter, indicating it is still in a pre-revenue, development-heavy phase.
• The decrease in R&D expenses was partly attributed to a strategic pause on clinical trial-related activities for the INB-400 program last year, which could imply a slowdown in certain development areas.

Risks

• Risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as the ability to meet anticipated deadlines and milestones.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of product candidates.
• The risk that the company may be unable to raise additional capital and could be forced to delay, further reduce, or explore other strategic options for certain development programs, or even terminate operations.
• The ability to continue to operate as a going concern.
• The risk that the company may not realize the intended benefits of its DeltEx platform.
• Uncertainty regarding the availability and timing of results from preclinical studies and clinical trials.
• Whether the outcomes of preclinical studies will be predictive of clinical trial results.
• Whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
• The risk that trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects arising from the testing or use of product candidates.
• The uncertainty of regulatory approvals to conduct trials or to market products.
• Reliance on third parties, including licensors and clinical research organizations.

Future Outlook

The company aims to accelerate enrollment for the INB-100 Phase 1 trial and believes INB-619 has the potential for deep B cell depletion and immune reset with an improved safety profile, allowing for higher doses. It remains focused on developing next-generation gamma-delta T cell therapies to redefine immune modulation and improve patient outcomes, with upcoming data presentations for INB-200/400 and INB-619.

Management Comments

• "During the quarter, we continued to execute on our goal of developing next-generation gamma-delta T cell therapies." William Ho, CEO and co-founder.
• "Our focus on the novel biology of gamma-delta T cells underscores our advancements along with the strength and versatility of our DeltEx platform." William Ho, CEO and co-founder.
• "This quarter, we expanded our INB-100 clinical operations to additional sites to accelerate enrollment, and we reported compelling preclinical data at the 2025 ACR Convergence Meeting." William Ho, CEO and co-founder.
• "Our INB-619 program is a novel and differentiated program in a sea of CD3-based TCEs that have yet to achieve immune reset in the autoimmune disease setting." William Ho, CEO and co-founder.
• "We remain focused on delivering the next generation of gamma-delta T cell therapies designed to redefine immune modulation and improve patient outcomes." William Ho, CEO and co-founder.

Industry Context

IN8bio operates in the highly competitive and innovative field of T cell immunotherapies, specifically focusing on gamma-delta T cells, which are a specialized population with unique properties. The development of T cell engagers like INB-619 for autoimmune diseases and oncology positions the company against both established CD3-directed engagers and emerging cell therapies. The emphasis on minimal cytokine release and potential for immune reset with INB-619 suggests an attempt to address safety and efficacy limitations observed in current treatments, potentially offering a differentiated approach in areas like systemic lupus erythematosus (SLE) and B cell depletion.

Comparison to Industry Standards

• INB-619 demonstrated equivalent potency to FDA-approved commercial CD19 and CD20 engagers, specifically blinatumomab and mosunetuzumab, in achieving complete B cell elimination in preclinical SLE donor models.
• INB-619's minimal cytokine release profile suggests an improved safety advantage over conventional CD3-directed engagers currently in development, which often face challenges with cytokine release syndrome.
• The targeted immune activation and cytokine-sparing design of INB-619 could allow for higher doses and deeper B cell depletion, potentially achieving an immune reset not yet observed with other protein engagers.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced net loss, increased cash, positive preclinical data, and pipeline advancement. However, dilution risk exists due to the reverse stock split and potential future capital raises.
• Patients: Potential benefit from the advancement of gamma-delta T cell therapies for cancer and autoimmune diseases, particularly with INB-619's improved safety profile and INB-100's accelerated enrollment.
• Employees: Continued employment and focus on strategic pipeline programs.
• Creditors/Suppliers: Improved cash position may enhance short-term financial stability.

Next Steps

• Present updated Phase 1 and 2 data from the INB-200/400 program in newly diagnosed GBM at the SNO Annual Meeting (November 19-23, 2025).
• Present additional preclinical data from the INB-619 gamma-delta T cell engager program in oncology at the American Society of Hematology (ASH) Annual Meeting (December 6-9, 2025).
• Continue to accelerate patient enrollment for the Phase 1 INB-100 trial.
• Advance the proprietary gamma-delta T cell platform and pipeline.

Key Dates

Recommendation

While IN8bio demonstrated improved financial performance with a reduced net loss and increased cash, and presented promising preclinical data for INB-619, it remains a clinical-stage company with significant R&D expenses and ongoing net losses. The explicit mention of risks related to capital raises and clinical trial uncertainties suggests a cautious approach. The positive preclinical data and accelerated trial enrollment are encouraging, but the company is still far from commercialization. A "hold" recommendation reflects the balance between these positive developments and the inherent risks of a pre-revenue biotech, awaiting further clinical data and clarity on long-term funding.

Keywords

IN8bio, INAB, gamma-delta T cell therapy, cancer, autoimmune diseases, INB-619, INB-100, INB-200, INB-400, glioblastoma, leukemia, biopharmaceutical, clinical-stage, Q3 2025 earnings, financial results, preclinical data, clinical trials, DeltEx platform, CD19 targeting, B cell depletion, cytokine release, SNO Annual Meeting, ASH Annual Meeting, SEC filing, 8-K